This project was completed by Intensity. Intensity joined Secretariat on February 1, 2023.
Two generic drug companies participated in an “at-risk” launch of generic versions of a multi-billion dollar gastroesophageal reflux drug. The generic drug companies launched “at-risk” by selling product after receiving FDA marketing approval, but while claims of patent infringement were still pending. A previous jury found that the patent-in-suit was valid and infringed, making economic damages the central remaining issue in the case.
Intensity calculated the profits that the branded drug company lost as a result of sales of generic versions of the branded drug. As part of its lost profits analysis, Intensity performed a reconstruction of a “but-for world” in which the infringement never occurred.
Reconstruction of the but-for world became an economic issue in the case due to the timing and complexity of marketplace events. The first generic company launched its product in large quantities, but stopped selling just days later. The second generic company waited to launch its generic product until the day after the branded company launched its own generic product. The first generic resumed sales of its product a number of months later. Intensity performed an analysis to quantify the economic effects of these marketplace events on lost sales and lost profits.
Our work involved quantification of the unit sales and prices that the branded company would have realized in the but-for world. The analysis included a determination of unit sales that were lost as a result of generic entry as well as additional unit sales that were made as result of the generic entry. Similarly, we performed an analysis of price erosion to determine the prices that the branded drug would have been sold at if competing generic versions had not been sold. We specifically examined the factors influencing price differences that occurred upon generic entry.
This project also involved an analysis of the economic impact of corporate structure and transfer pricing on lost profits.
Highlights and Takeaways from CBV CONNECT 2025
At the CBV CONNECT 2025 Conference in Toronto, we had the privilege of presenting multiple panels, engaging with fellow business valuation professionals, and exploring the latest developments shaping the future of the industry. We’ve compiled key takeaways from our time at CONNECT 2025 below, highlighting critical insights from our speaking engagements and the emerging trends […]
56 Secretariat experts were recognized in the Lexology Index 2025 Construction report as leading experts, lauded for their elite expertise, leadership, and client service. 12 of our experts were named as Global Elite Thought Leaders in the report, earning us the No. 1 spot in that category out of more than 650 ranked firms.
Inside RDNA4, Charting Ukraine’s USD 524 Billion Path to Recovery
In this article, Volodymyr Monastyrskyy from Dentons, Chris Richardson and Sulaxmi Rai from Secretariat break down RDNA4’s findings. They discuss where investment is most needed and what it will take to move from damage to development.